CA
BDTX icon

Cliff Asness’s Black Diamond Therapeutics BDTX Stock Holding History

Cliff Asness’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-18,026
Closed -$68.3K – 3574
2025
Q3 		$68.3K Sell
18,026
-195,211
-92% -$571K ﹤0.01% 3401
2025
Q2 		$529K Buy
213,237
+159,115
+294% +$307K ﹤0.01% 2592
2025
Q1 		$83.9K Buy
+54,122
New +$113K ﹤0.01% 3040
2024
Q4 		– Sell
-15,692
Closed -$68.3K – 2875
2024
Q3 		$68.3K Buy
+15,692
New +$85.4K ﹤0.01% 2688
2022
Q3 		– Sell
-18,663
Closed -$46K – 2200
2022
Q2 		$46K Buy
18,663
+4,773
+34% +$11.1K ﹤0.01% 2138
2022
Q1 		$38K Buy
+13,890
New +$50.7K ﹤0.01% 2190

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Cliff Asness's BDTX Position: Q4 2025 in Review

Cliff Asness sold out of Black Diamond Therapeutics (BDTX) in Q4 2025, closing a stake of 18,026 shares — an estimated $68.3K sold.

Cliff Asness first reported a position in BDTX in Q1 2022 and held it in 6 quarters. The position peaked at $529K in Q2 2025. 104 funds tracked by Wall St. Rank hold BDTX as of Q4 2025.

  • Cliff Asness reported no remaining Black Diamond Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Cliff Asness sold 18,026 Black Diamond Therapeutics shares in Q4 2025, an estimated $68.3K.
  • Cliff Asness first reported a position in Black Diamond Therapeutics in Q1 2022 and held it in 6 quarters.
  • Cliff Asness's Black Diamond Therapeutics position peaked at $529K in Q2 2025.
  • 104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q4 2025.

Based on AQR Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.